Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients With Refractory Aggressive Non-Hodgkin Lymphoma (NHL): Long-Term Follow-Up of the Pivotal Zuma-1 Trial

Biology of Blood and Marrow Transplantation - Netherlands
doi 10.1016/j.bbmt.2017.12.644
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Outcomes of Patients ≥ 65 Years of Age in Zuma-1, a Pivotal Phase 1/2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Refractory Large B Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Preliminary Results of Earlier Steroid Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Large B Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Safety and Efficacy of Axicabtagene Ciloleucel (Axi-Cel) in Older Patients: Results From the Us Lymphoma Car-T Consortium

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Product Characteristics Associated With in Vivo Expansion of Anti-Cd19 Car T Cells in Patients Treated With Axicabtagene Ciloleucel (Axi-Cel)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma

Clinical Cancer Research
Cancer ResearchOncology
2018English

Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (Nhl) With Lisocabtagene Maraleucel in the Outpatient Setting: Results From Two Phase 2 Trials

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Long-Term Outcome of Patients With Relapsed/Refractory B-Cell Non- Hodgkin Lymphoma Treated With Bispecific Antibody Blinatumomab in a Phase I Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Long-Term Follow-Up of Patients With Non-Hodgkin Primary Diffuse Large B-Cell Lymphoma of the Stomach: Better Outcome After Immunochemotherapy

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy